About Liraglutide
Class: GLP-1 RA (daily)
Brand/Manufacturer: Generic
Dosing: Daily subcutaneous
Mean weight loss: 8.0%
Pivotal trial: SCALE, NEJM 2015
Liraglutide was the first once-daily GLP-1 RA approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). Mean weight loss in the SCALE trial was 8.0% at 56 weeks. Cardiovascular outcome benefit established in LEADER. Now largely superseded by weekly semaglutide and tirzepatide for weight management.
Mechanism of action
Liraglutide acts on the GLP-1 receptor (and GIP receptor in the case of tirzepatide), producing four primary effects: central appetite suppression, delayed gastric emptying, glucose-dependent insulin release, and glucagon suppression. The combined effect on body weight averaged across pivotal trials is 8.0% body weight reduction at the trial endpoint.
Clinical evidence
The pivotal trial supporting Liraglutide's weight management indication is SCALE, NEJM 2015. Detailed data including primary and secondary endpoints, population characteristics, and adverse event frequencies is summarized on our clinical research page.
How to access Liraglutide via telehealth
Liraglutide is available through several U.S. telehealth providers. Compounded versions (where applicable) are dispensed by 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities. NexLife is our editorial #1 pick for Liraglutide access — see the side panel for details.
FAQ
Is Liraglutide FDA-approved?
The brand-name versions of Liraglutide are FDA-approved for the indications listed above. Compounded versions are not FDA-approved.
How much does Liraglutide cost?
Brand-name Liraglutide typically costs hundreds to over a thousand dollars per month at retail. Compounded equivalents (where available) cost significantly less. See our cost guide for verified May 2026 pricing.